‘+25 International Guests Will Be Sharing their Knowledge at SOLACI-SOCIME 2022

SOLACI-SOCIME 2022

+25 INTERNATIONAL GUESTS WILL BE SHARING THEIR KNOWLEDGE AT SOLACI-SOCIME 2022

Why is SOLACI-SOCIME 2022 an unmissable event for Latin American interventional cardiologists? Because it is the perfect place for the main experts and opinion leaders in the field to meet. 

This year, over 25 guests from Europe, Asia and the United States will be attending our annual meeting and will be sharing their knowledge and experience in innovative scientific sessions.

Make part of the most relevant meeting of interventional cardiology in Latin America and take your career to the next level!

Register with 15% discount 

*Pre-register until Friday, July 22. Past this date, you will be able to register face to face *as of August 3* at Expo Santa Fe

CHECK OUR INTERNATIONAL GUESTS

SOLACI-SOCIME 2022

Register with 15% discount 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

The El Salvador 2024 Sessions are coming soon

The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Virtual Event SOLACI-Medtronic | The Visible Heart Lab

We invite you to participate in a new virtual activity organized in collaboration with Medtronic, focused on "The Visible Heart Lab" and dedicated to...

SOLACI-CACI 2024 – Presentations day 3

Discover the highlights of the third day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at the Hilton Hotel in Buenos Aires, Argentina. Dr....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...